• SENSEX
    NIFTY 50
Earnings

Q4FY20 preview: Pharma companies to decent earnings growth amid COVID-19 disruptions

Updated : April 20, 2020 06:59 PM IST

Panic buying of chronic medicines in anticipation of an extended lockdown would aid volumes somewhat.
Domestic sales are expected to expand by 10–11 percent YoY led by pricing growth across the board.
US sales are expected to drop 2.4 percent on a QoQ basis in 4QFY20, largely weighed by a reducing rate of approvals, brokerages said.
Q4FY20 preview: Pharma companies to decent earnings growth amid COVID-19 disruptions

You May Also Like

Live TV
Advertisement